Tags

Type your tag names separated by a space and hit enter

Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Transplantation. 2012 Oct 27; 94(8):830-6.T

Abstract

BACKGROUND

Levels of fibroblast growth factor (FGF)-23, a phosphaturic hormone, increase from the early stages of CKD and are dramatically elevated in dialysis patients. Excessive FGF-23 may be involved in the hypophosphatemia and inappropriately low calcitriol levels observed after kidney transplantation (KT).This prospective observational cohort study was carried out to determine whether there are any differences in the changes in FGF-23 levels after surgery in KT recipients according to whether they were or not on dialysis before transplantation and to assess the influence of FGF-23 in the development of posttransplantation hypophosphatemia.

METHODS

Consecutive KT recipients at the Hospital Clinic of Barcelona were recruited. Patients developing delayed graft function were excluded. Mineral metabolism parameters, including C-terminal fragment of FGF-23, intact parathyroid hormone, and 1,25(OH)(2)D(3), were measured in 72 KT recipients (58 on dialysis before transplantation and 14 preemptive transplant recipients) at baseline, on day 15, and at 1, 3, and 6 months after transplantation. No patients received treatment with calcimimetics, bisphosphonates, vitamin D, or phosphate supplementation during the follow-up.

RESULTS

FGF-23 decreased significantly in the first month after transplantation. Baseline and FGF-23 levels within the first posttransplantation month were lower in preemptive transplant recipients than in patients on dialysis at transplantation. Serum phosphate levels were lower in dialysis patients until the third month after transplantation. Pretransplantation FGF-23 was the main predictor of posttransplantation phosphate blood levels.

CONCLUSIONS

FGF-23 levels and the risk of developing posttransplantation hypophosphatemia were lower in preemptive kidney transplant recipients than in patients on dialysis before transplantation.

Authors+Show Affiliations

Nephrology Department, Hospital Clinic of Barcelona, Spain. xbarros@clinic.ub.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23018879

Citation

Barros, Xoana, et al. "Earlier Decrease of FGF-23 and Less Hypophosphatemia in Preemptive Kidney Transplant Recipients." Transplantation, vol. 94, no. 8, 2012, pp. 830-6.
Barros X, Torregrosa JV, Martínez de Osaba MJ, et al. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. Transplantation. 2012;94(8):830-6.
Barros, X., Torregrosa, J. V., Martínez de Osaba, M. J., Casals, G., Paschoalin, R., Durán, C. E., & Campistol, J. M. (2012). Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. Transplantation, 94(8), 830-6. https://doi.org/10.1097/TP.0b013e318264fc08
Barros X, et al. Earlier Decrease of FGF-23 and Less Hypophosphatemia in Preemptive Kidney Transplant Recipients. Transplantation. 2012 Oct 27;94(8):830-6. PubMed PMID: 23018879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. AU - Barros,Xoana, AU - Torregrosa,Jose Vicente, AU - Martínez de Osaba,María J, AU - Casals,Gregori, AU - Paschoalin,Raphael, AU - Durán,Carlos E, AU - Campistol,Josep M, PY - 2012/9/29/entrez PY - 2012/9/29/pubmed PY - 2012/12/28/medline SP - 830 EP - 6 JF - Transplantation JO - Transplantation VL - 94 IS - 8 N2 - BACKGROUND: Levels of fibroblast growth factor (FGF)-23, a phosphaturic hormone, increase from the early stages of CKD and are dramatically elevated in dialysis patients. Excessive FGF-23 may be involved in the hypophosphatemia and inappropriately low calcitriol levels observed after kidney transplantation (KT).This prospective observational cohort study was carried out to determine whether there are any differences in the changes in FGF-23 levels after surgery in KT recipients according to whether they were or not on dialysis before transplantation and to assess the influence of FGF-23 in the development of posttransplantation hypophosphatemia. METHODS: Consecutive KT recipients at the Hospital Clinic of Barcelona were recruited. Patients developing delayed graft function were excluded. Mineral metabolism parameters, including C-terminal fragment of FGF-23, intact parathyroid hormone, and 1,25(OH)(2)D(3), were measured in 72 KT recipients (58 on dialysis before transplantation and 14 preemptive transplant recipients) at baseline, on day 15, and at 1, 3, and 6 months after transplantation. No patients received treatment with calcimimetics, bisphosphonates, vitamin D, or phosphate supplementation during the follow-up. RESULTS: FGF-23 decreased significantly in the first month after transplantation. Baseline and FGF-23 levels within the first posttransplantation month were lower in preemptive transplant recipients than in patients on dialysis at transplantation. Serum phosphate levels were lower in dialysis patients until the third month after transplantation. Pretransplantation FGF-23 was the main predictor of posttransplantation phosphate blood levels. CONCLUSIONS: FGF-23 levels and the risk of developing posttransplantation hypophosphatemia were lower in preemptive kidney transplant recipients than in patients on dialysis before transplantation. SN - 1534-6080 UR - https://www.unboundmedicine.com/medline/citation/23018879/Earlier_decrease_of_FGF_23_and_less_hypophosphatemia_in_preemptive_kidney_transplant_recipients_ L2 - https://doi.org/10.1097/TP.0b013e318264fc08 DB - PRIME DP - Unbound Medicine ER -